AZD-9291是GX选择性EGFR突变体YZ剂,对外显子19缺失型EGFR、L858R/T790M EGFR和野生型EGFR的IC50分别为12.92 nM,11.44 nM和493.8
所属靶点:L858R/T790M EGFR,Exon 19 deletion EGFR ,WT EGFR ;
特征:Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.
联系业务可加QQ:2880781534
lianxi